CXCR4, a downstream effector of RUNX2 transcription factor, presents an exciting and viable target in oral cancer, with both antagonists and CXCR4 directed imaging in the mature stage of development. The gene discussed is CXCR4; the disease is lip and oral cavity carcinoma.